Literature DB >> 27915093

Discoidin domain receptor 1 kinase activity is required for regulating collagen IV synthesis.

Corina M Borza1, Yan Su1, Truc-Linh Tran1, Ling Yu1, Nick Steyns2, Kayla J Temple2, Marcin J Skwark2, Jens Meiler2, Craig W Lindsley2, Brennan R Hicks1, Birgit Leitinger3, Roy Zent4, Ambra Pozzi5.   

Abstract

Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that binds to and is activated by collagens. DDR1 expression increases following kidney injury and accumulating evidence suggests that it contributes to the progression of injury. To this end, deletion of DDR1 is beneficial in ameliorating kidney injury induced by angiotensin infusion, unilateral ureteral obstruction, or nephrotoxic nephritis. Most of the beneficial effects observed in the DDR1-null mice are attributed to reduced inflammatory cell infiltration to the site of injury, suggesting that DDR1 plays a pro-inflammatory effect. The goal of this study was to determine whether, in addition to its pro-inflammatory effect, DDR1 plays a deleterious effect in kidney injury by directly regulating extracellular matrix production. We show that DDR1-null mice have reduced deposition of glomerular collagens I and IV as well as decreased proteinuria following the partial renal ablation model of kidney injury. Using mesangial cells isolated from DDR1-null mice, we show that these cells produce significantly less collagen compared to DDR1-null cells reconstituted with wild type DDR1. Moreover, mutagenesis analysis revealed that mutations in the collagen binding site or in the kinase domain significantly reduce DDR1-mediated collagen production. Finally, we provide evidence that blocking DDR1 kinase activity with an ATP-competitive small molecule inhibitor reduces collagen production. In conclusion, our studies indicate that the kinase activity of DDR1 plays a key role in DDR1-induced collagen synthesis and suggest that blocking collagen-mediated DDR1 activation may be beneficial in fibrotic diseases.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Collagen receptors; Fibrosis; Kidney injury; Mesangial cells; Partial renal ablation

Mesh:

Substances:

Year:  2016        PMID: 27915093      PMCID: PMC5329129          DOI: 10.1016/j.matbio.2016.11.009

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  41 in total

1.  Increased cell and matrix accumulation during atherogenesis in mice with vessel wall-specific deletion of discoidin domain receptor 1.

Authors:  Christopher Franco; Pamela J Ahmad; Guangpei Hou; Eric Wong; Michelle P Bendeck
Journal:  Circ Res       Date:  2010-05-06       Impact factor: 17.367

2.  Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice.

Authors:  Diana Rubel; Jenny Frese; Maria Martin; Alexander Leibnitz; Rainer Girgert; Nicolai Miosge; Beate Eckes; Gerhard-Anton Müller; Oliver Gross
Journal:  Matrix Biol       Date:  2014-01-27       Impact factor: 11.583

3.  Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease.

Authors:  Oliver Gross; Rainer Girgert; Bogdan Beirowski; Matthias Kretzler; Hee Gyung Kang; Jenny Kruegel; Nicolai Miosge; Ann-Christin Busse; Stephan Segerer; Wolfgang F Vogel; Gerhard-Anton Müller; Manfred Weber
Journal:  Matrix Biol       Date:  2010-03-20       Impact factor: 11.583

Review 4.  Cell Receptor-Basement Membrane Interactions in Health and Disease: A Kidney-Centric View.

Authors:  Corina M Borza; Xiwu Chen; Roy Zent; Ambra Pozzi
Journal:  Curr Top Membr       Date:  2015       Impact factor: 3.049

5.  Exploring the collagen-binding site of the DDR1 tyrosine kinase receptor.

Authors:  Rahim Abdulhussein; Catherine McFadden; Pablo Fuentes-Prior; Wolfgang F Vogel
Journal:  J Biol Chem       Date:  2004-05-10       Impact factor: 5.157

6.  Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.

Authors:  Yongmun Choi; Farisa Syeda; John R Walker; Patrick J Finerty; Dominic Cuerrier; Amy Wojciechowski; Qingsong Liu; Sirano Dhe-Paganon; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2009-05-13       Impact factor: 2.823

7.  Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6.

Authors:  Cristina Hidalgo-Carcedo; Steven Hooper; Shahid I Chaudhry; Peter Williamson; Kevin Harrington; Birgit Leitinger; Erik Sahai
Journal:  Nat Cell Biol       Date:  2010-12-19       Impact factor: 28.824

8.  Integrin α1/Akita double-knockout mice on a Balb/c background develop advanced features of human diabetic nephropathy.

Authors:  Ling Yu; Yan Su; Paisit Paueksakon; Huifang Cheng; Xiwu Chen; Hongtao Wang; Raymond C Harris; Roy Zent; Ambra Pozzi
Journal:  Kidney Int       Date:  2012-02-01       Impact factor: 10.612

9.  Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.

Authors:  Hideki Terai; Li Tan; Ellen M Beauchamp; John M Hatcher; Qingsong Liu; Matthew Meyerson; Nathanael S Gray; Peter S Hammerman
Journal:  ACS Chem Biol       Date:  2015-09-25       Impact factor: 5.100

Review 10.  Discoidin domain receptor functions in physiological and pathological conditions.

Authors:  Birgit Leitinger
Journal:  Int Rev Cell Mol Biol       Date:  2014       Impact factor: 6.813

View more
  14 in total

1.  Discoidin Domain Receptor 2, a Potential Therapeutic Target in Lung Fibrosis.

Authors:  Corina M Borza; Ambra Pozzi; Erin J Plosa
Journal:  Am J Respir Cell Mol Biol       Date:  2018-09       Impact factor: 6.914

2.  Novel Targets for Therapy of Renal Fibrosis.

Authors:  Niki Prakoura; Juliette Hadchouel; Christos Chatziantoniou
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

Review 3.  Matrix modeling and remodeling: A biological interplay regulating tissue homeostasis and diseases.

Authors:  Nikos K Karamanos; Achilleas D Theocharis; Thomas Neill; Renato V Iozzo
Journal:  Matrix Biol       Date:  2018-08-18       Impact factor: 11.583

4.  Discovery of VU6015929: A Selective Discoidin Domain Receptor 1/2 (DDR1/2) Inhibitor to Explore the Role of DDR1 in Antifibrotic Therapy.

Authors:  Daniel E Jeffries; Corina M Borza; Anna L Blobaum; Ambra Pozzi; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2019-11-25       Impact factor: 4.345

5.  The Extracellular Matrix Receptor Discoidin Domain Receptor 1 Regulates Collagen Transcription by Translocating to the Nucleus.

Authors:  Manuel Chiusa; Wen Hu; Hong-Jun Liao; Yan Su; Corina M Borza; Mark P de Caestecker; Nataliya I Skrypnyk; Agnes B Fogo; Vadim Pedchenko; Xiyue Li; Ming-Zhi Zhang; Billy G Hudson; Trayambak Basak; Roberto M Vanacore; Roy Zent; Ambra Pozzi
Journal:  J Am Soc Nephrol       Date:  2019-08-05       Impact factor: 10.121

Review 6.  Periostin and Discoidin Domain Receptor 1: New Biomarkers or Targets for Therapy of Renal Disease.

Authors:  Niki Prakoura; Christos Chatziantoniou
Journal:  Front Med (Lausanne)       Date:  2017-05-09

7.  Inhibitors of Discoidin Domain Receptor (DDR) Kinases for Cancer and Inflammation.

Authors:  William A Denny; Jack U Flanagan
Journal:  Biomolecules       Date:  2021-11-10

8.  Inhibition of discoidin domain receptors by imatinib prevented pancreatic fibrosis demonstrated in experimental chronic pancreatitis model.

Authors:  Sapana Bansod; Mohd Aslam Saifi; Chandraiah Godugu
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

9.  Genomic Divergence in Swedish Warmblood Horses Selected for Equestrian Disciplines.

Authors:  Michela Ablondi; Susanne Eriksson; Sasha Tetu; Alberto Sabbioni; Åsa Viklund; Sofia Mikko
Journal:  Genes (Basel)       Date:  2019-11-27       Impact factor: 4.096

Review 10.  The role of basement membranes in cardiac biology and disease.

Authors:  Erin Boland; Fabio Quondamatteo; Tom Van Agtmael
Journal:  Biosci Rep       Date:  2021-08-27       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.